Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 27, Number 2—February 2021
Research Letter

COVID-19 Infection Control Measures in Long-Term Care Facility, Pennsylvania, USA

Scott T. Shimotsu, Ariel R.L. Johnson, Ethan M. Berke, and Daniel O. GriffinComments to Author 
Author affiliations: UnitedHealth Group, Minnetonka, Minnesota, USA (S.T. Shimotsu, A.R.L. Johnson, E.M. Berke, D.O. Griffin); Columbia University College of Physicians and Surgeons, New York, New York, USA (D.O. Griffin); ProHealth Care Optum, New York (D.O. Griffin)

Suggested citation for this article

Abstract

Residents of long-term care facilities are at risk for coronavirus disease. We report a surveillance exercise at such a facility in Pennsylvania, USA. After introduction of a testing strategy and other measures, this facility had a 17-fold lower coronavirus disease case rate compared with those of neighboring facilities.

The coronavirus disease pandemic created an urgency to accelerate data collection to better understand the outbreak in vulnerable populations and identify best strategies for containment (1). Data suggested that older adults living in long-term care facilities (LTCFs) were at high risk for infection (2,3). Guidance issued by the Centers for Disease Control and Prevention outlined the importance of restricting visitation, canceling group activities, and implementing symptom screening for residents and healthcare workers (HCWs). Mitigation was put in place to limit visitors to these facilities; however, residents rely on staff, who may be exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outside the facility. As was seen in Seattle, Washington, USA, during early 2020 (4), once SARS-CoV-2 is introduced into a LTCF, infection and death can be common. We hypothesized that high-risk persons in group living situations would benefit from regular, proactive monitoring for COVID-19 to prevent infection and the high transmission rates that occur in LTCF (5).

In this surveillance exercise performed at Twin Pines, an LTCF in Chester County, Pennsylvania, USA, we selected participants based on their association with this LTCF through employment, frequent visits (e.g., deliveries, essential care), or residence. Although we were solely observing the impact of facility-wide quality improvement, we obtained approval from the UnitedHealth Group Research and Development Institutional Review Board (Minnetonka, Minnesota, USA) and proceeded with its oversight. All persons involved in daily activities of the LTCF, including residents, employees, and visitors, were asked to participate. They completed daily symptom surveys and provided samples by nasal swab. If a participant had trouble with the self-administered sampling, a healthcare provider assisted by overseeing or performing the process. Healthcare providers collected nasal swab tests from residents twice per week and staff daily for 10 weeks (June 23–October 1, 2020). All symptom surveys and tests were conducted at the LTCF.

In addition to all 92 of the staff (nurses, therapists, and other personnel), 9 frequent visitors completed a survey and test every time they entered the facility during the surveillance period. Delivery persons who did not enter the building were not required to participate. The use of personal protective equipment (PPE) was required for all staff and visitors; PPE consisted of masking at all times while in the facility and wearing N95 masks in isolation and quarantine areas. Strict hygiene practices for the staff and twice-daily cleaning were enforced. Only full-time staff worked during this period; no per-diem staff were engaged. New residents were admitted to the facility during the observation, but they were required to quarantine for 14 days or until they had 2 negative tests. Family visits and group activities were not allowed.

During this surveillance period a total of 5,625 nasal swabs were evaluated. We processed swab test specimens by reverse transcription PCR using a SARS-CoV-2 nucleic acid amplification test platform (LabCorp, https://www.labcorp.com). Results were provided to participants; typical turnaround time was 3 days. Two of 111 residents who tested positive had confirmed positive SARS-CoV-2 tests (results available in 1 day for the first infected resident and 7 days for the second; the delay for the second patient resulted from increased testing and limited capacity). The 2 patients were isolated for 10 days, after which they were retested until they tested negative. Staff who tested positive waited 10 days from their initial positive test and were required to have 2 negative tests before returning to work. Frequent testing and symptom surveys enabled the detection of 1 infected staff member early enough to prevent spread within the facility. Based on data obtained September 28–October 9, 2020, this LTCF’s case number was 17 times lower than that of neighboring facilities when adjusted for the facility census.

Although our findings were encouraging, several aspects of our study need confirmation in future studies. The introduction of testing, questionnaires, and infection control measures may not fully explain the low prevalence of SARS-CoV-2 infection. We do not have a clear explanation for how the 2 residents became infected after the introduction of these measures; we were unable to determine whether surveys were useful tools. It is possible that routine testing discouraged persons with symptoms from visiting. We observed a very low rate of positive tests in the LTCF staff; only 1 staff member tested positive. Potential explanations for this low rate could be that testing had an impact on behavior, symptom screening kept ill staff home, or the virus was less prevalent in the community surrounding the LTCF. Although symptom surveys were used and absentee rates were normal, staff did not report symptoms as a reason for missed work. Despite these limitations, this study suggests that a proper testing strategy coupled with other measures may result in protection of vulnerable populations.

Dr. Shimotsu is an epidemiologist at United Health Group. His research areas include clinical care model development, chronic disease treatment, and social determinants of chronic disease. 

Top

References

  1. Lai  C-C, Wang  J-H, Ko  W-C, Yen  M-Y, Lu  M-C, Lee  C-M, et al. COVID-19 in long-term care facilities: an upcoming threat that cannot be ignored. J Microbiol Immunol Infect. 2020;53:4446.
  2. Wortham  JM, Lee  JT, Althomsons  S, Latash  J, Davidson  A, Guerra  K, et al. Characteristics of persons who died with COVID-19–United States, February 12–May 18, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:9239. DOIPubMed
  3. Fisman  DN, Bogoch  I, Lapointe-Shaw  L, McCready  J, Tuite  AR. Risk factors associated with mortality among residents with coronavirus disease 2019 (COVID-19) in long-term care facilities in Ontario, Canada. JAMA Netw Open. 2020;3:e2015957.
  4. Rossen  LM, Branum  AM, Ahmad  FB, Sutton  P, Anderson  RN. Excess deaths associated with COVID-19, by age and race and ethnicity—United States, January 26-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:15227. DOIPubMed
  5. McMichael  TM, Clark  S, Pogosjans  S, Kay  M, Lewis  J, Baer  A, et al.; Public Health – Seattle & King County, EvergreenHealth, and CDC COVID-19 Investigation Team. COVID-19 in a long-term care facility—King County, Washington, February 27–March 9, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:33942. DOIPubMed

Top

Suggested citation for this article: Shimotsu ST, Johnson ARL, Berke EM, Griffin DO. COVID-19 infection control measures in long-term care facility, Pennsylvania, USA. Emerg Infect Dis. 2021 Feb [date cited]. https://doi.org/10.3201/eid2702.204265

DOI: 10.3201/eid2702.204265

Table of Contents – Volume 27, Number 2—February 2021

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Daniel Griffin, Columbia University Irving Medical Center—Medicine, 701 W 168th St, HHSC 1310, New York, NY 10032-3784, USA

Send To

10000 character(s) remaining.

Top

Page created: November 19, 2020
Page updated: November 21, 2020
Page reviewed: November 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external